Erwin Loh: Triple Combination Therapy Shows Major Benefit in Preventing Recurrent Stroke
Erwin Loh, President of Royal Australasian College of Medical Administrators, shared a post on LinkedIn about a recent article by The Trident Research Group, published in The New England Journal of Medicine:
”Low-dose triple-pill cut risk of recurrent stroke by about 40 percent, global trial shows
Patients treated with 3-in-1 blood pressure pill experienced a third less major adverse cardiovascular events.
Treatment with GMRx2, a single pill combination of three low-dose blood pressure medicines, significantly reduced the risk of another stroke in patients with intracerebral haemorrhage and high blood pressure.
Results from the TRIDENT randomised controlled trial, led by The George Institute for Global Health, were published today in The New England Journal of Medicine.
Source in comments.”
Title: Three Low-Dose Antihypertensive Agents in a Single Pill after Intracerebral Hemorrhage
Author: The Trident Research Group
Stay updated on all scientific advances with Hemostasis Today.
-
Apr 24, 2026, 17:51Mostafa Faisal Mohammed Saleh: Exploring the Impact of PNH Clones in Aplastic Anemia Across Different Treatment Strategies
-
Apr 24, 2026, 17:35Dawn Faller: Strengthening Global Collaboration in Apheresis at the 2026 ASFA and WAA Joint Meeting
-
Apr 24, 2026, 17:30Omar Adwan: Easy-to-Remember Tips for MCV
-
Apr 24, 2026, 17:07Melissa Hollo: Revolutionizing Diagnostics Through Real-Time Anemia Management at Executive War College
-
Apr 24, 2026, 17:03Oscar William-Donkor: Faith, Blood and Choice
-
Apr 24, 2026, 17:01Julie Rayes: Presenting Our Data at the 12th Symposium on Hemostasis
-
Apr 24, 2026, 16:56Nazish Saqlain: Hands-on Training Workshop in Transfusion Medicine and Immunohematology
-
Apr 24, 2026, 16:49Michael Greger: Most Heart Attacks Are Triggered by Non-Obstructive Plaques
-
Apr 24, 2026, 16:06Maxime Dely: Venous Access in Apheresis Technology Isn’t Everything